Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE.
배상철
제목
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE.